[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-retention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-retention":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,56,87,120,157,188,217,244,269,293,324,351,376,401,424,459,480,511,539],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100053458","selective-median-lobe-surgery-outcomes-study-100053458",false,"NCT07699718","Selective Median Lobe Surgery Outcomes Study","UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation","UNVEIL-BPO","Inclusion Criteria:\n\n* Male patients aged 45 years or older.\n\n  * Moderate-to-severe lower urinary tract symptoms due to benign prostatic obstruction or urinary retention requiring transurethral surgery.\n  * Preoperative findings suggesting median lobe-dominant or median lobe-related obstruction.\n  * Planned selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care.\n  * Available baseline International Prostate Symptom Score, uroflowmetry and\u002For postvoid residual volume, prostate volume, intravesical prostatic protrusion measurement, and cystoscopic assessment.\n  * Ability to provide written informed consent and comply with the follow-up schedule.\n\nExclusion Criteria:\n\n* Previous prostate surgery for benign prostatic hyperplasia.\n* Known urethral stricture requiring treatment before or during the index procedure.\n* Known neurogenic lower urinary tract dysfunction.\n* Active prostate cancer or bladder cancer requiring treatment that may confound urinary outcomes.\n* Planned complete TURP, complete HoLEP\u002FAEEP, or lateral lobe-dominant surgery.\n* Severe kissing lateral lobe obstruction considered to require complete surgery rather than selective median lobe surgery.\n* Inability to provide valid baseline or follow-up outcome data.","MALE","45 Years",{"count":20,"type":21},420,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery.\n\nThe study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months.\n\nThe main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.",[25,26,27,28,29],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Obstruction","Urinary Retention","Median Lobe Prostatic Enlargement",[31,32,33,34,35,36,37,38,39,40,41,42],"Median lobe","Intravesical prostatic protrusion","Selective median lobe surgery","Selective median lobe enucleation","Selective median lobe resection","TURP","HoLEP","Anatomical endoscopic enucleation of the prostate","Uroflowmetry","Postvoid residual","Clinical failure","Ejaculation preservation","NOT_YET_RECRUITING","2026-07-09",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-09-01",{"date":51,"type":21},"2030-12-01",{"name":53,"class":54},"Necmettin Erbakan University","OTHER",2,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100528645","effect-of-chlorhexidine-gluconate-bladder-instillations-in-patients-with-chronic-suprapubic-catheters-on-unplanned-healthcare-encounters-and-quality-of-life-100528645","NCT06163469","Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life","Instillation in Neurogenic Bladders to Decrease Unplanned Healthcare Encounters","Inclusion Criteria:\n\n* Indwelling suprapubic catheter with insertion date at least 1 year prior to study enrollment date.\n* History of urinary tract infections, treated for at least 1 positive urine culture in last 6 months\n\nExclusion Criteria:\n\n* Current radiographic evidence of urolithiasis\n* History of vesicoureteral reflux\n* History of renal transplantation\n* History of bladder augmentation\n* Inability to stop use of other rUTI prophylaxis treatments for the duration of their trial enrollment\n* Life expectancy of less than 12 months prior to consent.\n* Known hypersensitivity or allergy to chlorhexidine.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":66,"type":21},70,"INTERVENTIONAL",[69],"NA","The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are:\n\n1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients.\n2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life.\n\nPatients will undergo the treatment protocol during their routine suprapubic catheter exchanges.",[72,28],"Neurogenic Bladder",[74,75],"recurrent UTI","bladder irrigation","RECRUITING","2026-06-17",{"date":79,"type":47},"2026-06-18",{"date":81,"type":47},"2024-04-01",{"date":83,"type":21},"2027-12-31",{"name":85,"class":54},"Yale University",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":67,"phases":98,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":86},"100332538","phase-1-post-operative-urinary-retention-pour-following-thoracic-surgery-100332538","NCT03609580","Post-operative Urinary Retention (POUR) Following Thoracic Surgery","POUR","Inclusion Criteria:\n\nMales\n\n≥50 years old Planned surgical procedure of a minimally invasive thoracic surgical procedure (wedge resection, segmentectomy, lobectomy, pleural biopsy, or pleurodesis) Surgery scheduled more than 3 days from the time of consent\n\nExclusion Criteria:\n\n* Using Flomax already\n* Allergy to Flomax or sulfa drugs\n* Current use of alpha blockers or alpha agonists\n* Resting systolic blood pressure \\\u003C100\n* Orthostatic hypotension of \\>20mm Hg (millimeters of mercury) Systolic and\u002For 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent\n* Known diagnosis of congestive heart failure and valvular heart disease\n* History of prostate surgery (prostatectomy, trans-urethral resection)",true,"50 Years",{"count":97,"type":21},127,[99,100],"PHASE1","PHASE2","Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting in a bladder catheter (Foley). This is uncomfortable, and can lead to bleeding, infection, damage to the urethra and\u002For bladder and bladder spasm. The goal of this study is to attempt to prevent inability to urinate by giving patients a medication called Flomax (Tamusolin) every day beginning a week before surgery. That medication relaxes the prostate. It's approved by the Food and Drug Administration (FDA) to improve urinary flow in those with enlarged prostates. It is also commonly used in patients with bladder problems due to inability to urinate who have required a Foley.",[28],[104,105,106,107,108,109,110],"post operative urinary retention","inability to urinate","urinary retentions","lung cancer","VATs","Robotic Lung Surgery","lung resections","2026-06-09",{"date":113,"type":47},"2026-06-11",{"date":115,"type":47},"2018-05-07",{"date":117,"type":21},"2027-03-30",{"name":119,"class":54},"Hackensack Meridian Health",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":86},"100637509","effect-of-catheter-duration-on-prostate-laser-enucleation-surgery-outcomes-in-patients-with-urinary-retention-100637509","NCT07603011","Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Urinary Retention","Evaluation of the Effect of Catheter Duration on Prostate Laser Enucleation Surgery Outcomes in Patients With Indwelling Catheters Due to Urinary Retention: A Multicenter Study of the Minimally Invasive Urology Society","Inclusion Criteria:\n\n* Patients undergoing laser enucleation of the prostate, including HoLEP, ThuLEP or ThuFLEP procedures, who have an indwelling urinary catheter due to pre-operative urinary retention.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of neurogenic bladder or prostate cancer.",{"count":128,"type":21},54,"Benign Prostatic Obstruction (BPO) is a common condition in aging men that can lead to urinary retention, often requiring the use of an indwelling urinary catheter. While laser enucleation of the prostate (such as HoLEP, ThuLEP or ThuFLEP) is a safe and effective surgical treatment, it is not well understood how the length of time a patient spent with a urethral catheter before surgery affects the final surgical outcomes. By analyzing patient data from multiple centers of the Minimally Invasive Urology Society, this study aims to evaluate the impact of preoperative catheterization duration on functional outcomes.",[28,131],"Benign Prostate Obstruction (BPO)",[27,133,134,25,135,136,137,138,139,140,141,37,142,143,144,145,146,147],"BPO","BPH","Bladder Outlet Obstruction","Lower Urinary Tract Symptoms","Acute Urinary Retention","Urinary Catheterization","Catheter Duration","Holmium Laser Enucleation of the Prostate","Thulium Laser Enucleation of the Prostate","ThuLEP","Urology","Prospective Registry","Multicenter Study","ThuFLEP","Thulium Fiber Laser Enucleation of the Prostate","2026-05-16",{"date":150,"type":47},"2026-05-22",{"date":152,"type":47},"2026-02-04",{"date":154,"type":21},"2029-02-04",{"name":156,"class":54},"Eskişehir Osmangazi University Medicine Faculty Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":67,"phases":167,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100635690","comparing-clean-intermittent-self-catheterization-and-indwelling-catheterization-for-the-management-of-urinary-retention-before-bph-surgery-100635690","NCT07555964","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.l","CATHETERS","Inclusion Criteria:\n\n* Men over 50 years old;\n* Confirmed diagnosis of benign prostatic hyperplasia (BPH);\n* Prostate volume greater than 40 grams;\n* Presence of acute urinary retention with failure to wean from the catheter despite medical treatment with alpha-blocker for at least 48 hours\n* Indication for surgical management of BPH;\n* Patient affiliated with or a beneficiary of a social security scheme;\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patient with a history of prostate surgery (including BPH surgery), prostatic artery embolization or Urolift implant placement are not considered a history of prostate surgery;\n* Patient with symptomatic urethral stricture;\n* Patient with a bladder emptying disorder of neurogenic origin;\n* Patient with an anatomical contraindication to ICSC (urethral stricture, false urethral route);\n* Patient who had urine drainage by suprapubic catheter\n* Patient with motor, neurological, anatomical, or cognitive difficulties preventing the education or learning of ICSC;\n* Patient contraindicated for surgical management of their BPH;\n* Patient unable to understand the research documents and provide informed consent;\n* Persons subject to legal protection measures or placed under judicial protection.",{"count":166,"type":21},106,[69],"The CATHETERS trial is a multicenter, randomized, open-label superiority study comparing two methods of managing urinary retention before surgery for benign prostatic hyperplasia (BPH): clean intermittent self-catheterization (ICSC) versus indwelling catheter (IDC). The primary objective is to determine whether ICSC reduces the occurrence of infectious complications (urinary bacterial colonization requiring antibiotic therapy, urinary tract infection, or urosepsis) compared to IDC in men awaiting BPH surgery. A total of 106 patients will be enrolled across multiple centers in France, with follow-up extending to three months after surgery.",[170,28,138,171,172,173],"Prostatic Hyperplasia","Intermittent Urethral Catheterization","Urinary Tract Infections","Surgical Procedures",[134,175,176,177],"ICSC","IDC","Urinary Tractus Infection","2026-04-21",{"date":180,"type":47},"2026-04-29",{"date":182,"type":21},"2026-04-24",{"date":184,"type":21},"2028-04-24",{"name":186,"class":54},"University Hospital, Bordeaux",5,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":67,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":86},"100615468","evaluating-two-nursing-interventions-to-prevent-urinary-retention-after-spinal-anesthesia-100615468","NCT07293000","Evaluating Two Nursing Interventions to Prevent Urinary Retention After Spinal Anesthesia","Evaluation of the Effectiveness of Two Different Nursing Interventions in Preventing Urinary Retention in Patients Undergoing Spinal Anesthesia: Randomized Controlled Trial","Inclusion Criteria: Patients who meet all of the following criteria will be included:\n\n* Age 18 years or older\n* No diagnosis of urolithiasis, benign prostatic hyperplasia, neurogenic bladder, cancer, or other malignancy\n* No diagnosis of urinary tract infection within the last month\n* No history of prior urological surgery or surgery involving the sacral region\n* No history of urinary retention\n* Not using antidepressants, antipsychotics, muscarinic receptor antagonists, alpha-blockers, or similar medications\n* No contraindication for applying cold to the suprapubic area or massage to the sacral area (e.g., no pacemaker, bladder stimulator, or other sensitive electronic medical device in the sacral region)\n* No visual, hearing, cognitive, or perceptual impairment\n\nExclusion Criteria:Patients who meet any of the following criteria will be excluded:\n\n* Duration of surgery longer than 2 hours\n* Urinary catheterization performed preoperatively, intraoperatively, or postoperatively\n* Blood transfusion performed preoperatively, intraoperatively, or postoperatively\n* Development of complications such as hypothermia, bleeding, or other conditions that prevent the application of dry cold or sacral massage in the preoperative, intraoperative, or postoperative period\n* Transfer to the intensive care unit after surgery.",{"count":196,"type":21},105,[69],"The goal of this clinical trial is to learn whether two simple nursing methods can help prevent trouble emptying the bladder (acute urinary retention, AUR) after surgery with numbing medicine in the lower back (spinal anesthesia). Adults having surgery in the scrotum (scrotal), groin (inguinal), pelvic area, lower belly (lower abdominal), or bones and joints (orthopedic surgery) with spinal anesthesia will take part. After surgery, participants will be randomly placed into one of three groups: one group will receive a cold pack on the lower belly (suprapubic area), a second group will receive a gentle massage on the lower back over the tailbone (sacral area), and a third group will receive usual care only with no extra procedure. The same nurse researcher will provide the study care for all groups, check how well participants pass urine, use a small painless scan on the lower belly to see how much urine is in the bladder (portable bladder ultrasound), and record whether a tube in the bladder to drain urine (urinary catheter) is needed.",[200,28],"Postoperative Urinary Retention",[202,203,204,205,206,207],"Urinary retention","Postoperative urinary retention","Nursing Interventions","Bladder Volume Measurement Device","Cold Application","Sacral Massage","2026-03-31",{"date":210,"type":47},"2026-04-06",{"date":212,"type":21},"2026-05-15",{"date":214,"type":21},"2026-12-15",{"name":216,"class":54},"Istanbul University - Cerrahpasa",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":224,"minAge":64,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":67,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":55},"100621586","effect-of-voiding-position-standing-in-the-shower-vs-sitting-on-post-void-residual-urine-volume-pvr-after-removal-of-urinary-catheter-in-women-following-benign-vaginal-gynecologic-surgery-100621586","NCT07372547","Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery","Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery: A Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult women (≥18 years old).\n* Undergoing benign vaginal gynecologic surgery with indwelling catheter during surgery.\n* No bladder injury during surgery.\n* Ability and willingness to consent.\n* No known neurological or urinary conditions affecting voiding.\n* No active urinary tract infection at time of catheter removal.\n\nExclusion Criteria:\n\n* Bladder injury during surgery.\n* Neurological disease affecting bladder function.\n* Active urinary tract infection.\n* Inability to void either standing in shower or sitting (depending on randomization).","FEMALE","99 Years",{"count":227,"type":21},100,[69],"The goal of this clinical trial is to learn if voiding in a standing position in the shower, rather than sitting on a toilet, may reduce pain associated with the act of voiding, thereby facilitating micturition and decreasing both post-void residual volume and the risk of subsequent urinary retention in women that underwent benign vaginal surgeries.",[231,232,233,234,28],"Post-void Residual Volume","Recatheterization","Pain","UTI","2026-03-22",{"date":237,"type":47},"2026-03-25",{"date":239,"type":47},"2026-01-20",{"date":241,"type":21},"2028-01-20",{"name":243,"class":54},"Assuta Ashdod Hospital",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":224,"minAge":64,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":67,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":86},"100586645","comparison-of-urinary-flow-study-100586645","NCT06918067","Comparison of Urinary Flow Study","Comparison of Urinary Flow Speed Using 14 Fr Two Eyelet Coloplast Female SpeediCath Urinary Catheter Versus 14 Fr Coloplast Micro Zone Luja Female Catheter in Female Patients Using Intermittent Catheters","Inclusion Criteria:\n\n* Female\n* Regular use of intermittent catheters to empty bladder, for at least 1 month before enrolment\n* Age 18 years or older\n* Required to adhere to the intervention procedure and not participate in any other clinical studies throughout the duration of this study\n\nExclusion Criteria:\n\n* Severe urinary tract abnormalities (e.g. excessive production of urinary mucus\u002Fsediments\u002Fdebris)\n* Hypersensitive to the ingredients in the catheters being tested\n* Recent surgery, within 3 months\n* Currently being treated for urinary tract infection\n* Being pregnant or breastfeeding\n* Non-English speaking",{"count":252,"type":21},17,[69],"The purpose of this research study is to compare the urinary flow speed of two different female catheters in patients that use intermittent catheters to empty their bladder. The \"14 Fr Two Eyelet Coloplast Female SpeediCath Urinary Catheter\" will be compared to the \"14 Fr Coloplast Micro Zone Luja Female Catheter.\" Participants will have one study visit that should take about an hour and will also receive a follow-up telephone call about one week after the visit.",[28],[257,258,259],"catheter","intermittent catheterization","bladder","2026-03-03",{"date":262,"type":47},"2026-03-05",{"date":264,"type":47},"2025-11-06",{"date":266,"type":21},"2027-03",{"name":268,"class":54},"Wake Forest University Health Sciences",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":67,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":292},"100454698","pelvic-health-electrically-evoked-recording-peer-2-study-100454698","NCT05200923","Pelvic Health Electrically Evoked Recording (PEER) 2 Study","PEER 2","Inclusion Criteria:\n\nOveractive Bladder Criteria Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation\n6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.\n7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nNon-Obstructive Urinary Retention Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation\n6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nFecal Incontinence Inclusion Criteria\n\n1. 18 years of age or older\n2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\\* requiring an advanced evaluation\n3. Willing and able to provide signed and dated informed consent\n4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol\n5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation\n6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)\n\nNote\\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.\n\nExclusion Criteria:\n\nOveractive Bladder Criteria Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. History of diabetes unless the diabetes is well-controlled through diet and\u002For medications\n6. Have symptomatic urinary tract infection (UTI)\n7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component\n8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study\n9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n12. Women who are pregnant or planning to become pregnant\n13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)\n14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements\n\nNon-Obstructive Urinary Retention Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. History of diabetes unless the diabetes is well-controlled through diet and\u002For medications\n6. Have symptomatic urinary tract infection (UTI)\n7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n10. Women who are pregnant or planning to become pregnant\n11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)\n12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements\n\nFecal Incontinence Exclusion Criteria\n\n1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)\n2. Implanted with a neurostimulator, pacemaker or defibrillator\n3. Pelvic floor muscle dysfunction due to surgical intervention or injury\n4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)\n5. Have uncorrected high grade internal rectal prolapse\n6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months\n7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study\n8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy\n9. Women who are pregnant or planning to become pregnant\n10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements",{"count":277,"type":21},300,[69],"To collect physiological signals at several timepoints during the therapy evaluation period.",[281,282,28],"Overactive Bladder","Fecal Incontinence","2026-03-02",{"date":260,"type":47},{"date":286,"type":47},"2022-01-18",{"date":288,"type":21},"2026-12-18",{"name":290,"class":291},"MedtronicNeuro","INDUSTRY",7,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":299,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":67,"phases":302,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100489812","early-phase-1-post-operative-urinary-retention-pour-following-thoracic-oncological-surgery-100489812","NCT05657990","Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery","Inclusion Criteria:\n\n* Males\n* ≥55 years old\n* Planned thoracic oncological surgical procedure of a video assisted oncological surgical procedure for suspected or confirmed cancer.\n* Surgery scheduled more than 7 days from the time of consent\n\nExclusion Criteria:\n\n* Using Tamsulosin already\n* Known allergy to Tamsulosin or sulfa drugs\n* Current use of Boceprevir\n* Resting systolic blood pressure \\\u003C100\n* Orthostatic hypotension of \\>20mm Hg systolic and\u002For 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent\n* Known history of hypotension\n* Known diagnosis of congestive heart failure (CHF) and valvular heart disease\n* History of prior prostate surgery (prostatectomy, trans-urethral resection)","55 Years",{"count":301,"type":21},46,[303],"EARLY_PHASE1","This is a feasibility study looking at whether the use of Tamsulosin could lower the high incidence of postoperative urinary retention (POUR) in older men who undergo an oncological thoracic surgical procedure for suspected or confirmed cancer. In addition, the study will try to identify the time of resumption of presurgical urinary function post Tamsulosin administration.",[28],[28,307,308,309,310,311,312,313,314],"post surgery Urinary Retention","thoracic surgery","spontaneous voiding","bladder retention","Tamsulosin (FlomaxTM)","kidney injury","men undergoing thoracic oncological surgical procedure","BladderScanner","2026-02-06",{"date":317,"type":47},"2026-02-10",{"date":319,"type":47},"2023-04-03",{"date":321,"type":21},"2026-12",{"name":119,"class":54},4,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":332,"enrollmentInfo":333,"targetDuration":335,"studyType":22,"phases":4,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100622145","rectus-abdominis-detrusor-myoplasty-for-urinary-retention-100622145","NCT07379814","Rectus Abdominis Detrusor Myoplasty for Urinary Retention","To Investigate the Outcomes of Rectus Abdominis Flap Detrusor Myoplasty for Urinary Retention","RADM","Inclusion Criteria:\n\n* Hypo- or acontractility of the bladder documented on urodynamic testing\n* Injury \\>1 year ago for spinal cord injury patients, no improvement in contractility with time\n* Failed sacral nerve stimulation implant for urinary retention treatment (If previously implanted)\n* Irreversible non-neurogenic bladder acontractility\u002Fhypocontractility (i.e myogenic failure after chronic obstruction, aging, frailty, idiopathic)\n* Undergoing RADM\n\nExclusion Criteria:\n\n* Documented bladder outlet obstruction\n* Spinal cord lesion above T12\n* Upper motor neuron lesion (i.e. multiple sclerosis, stroke)\n* Rectus diastasis, significant abdominal wall hernia, or other anatomic barrier to rectus flap harvest\n* Life expectancy \\\u003C10 years\n* Pregnant at time of surgery","75 Years",{"count":334,"type":21},50,"1 Year","This investigates the outcomes of a surgical technique using the patient's own abdominal wall muscles to help contract the bladder in patients with urinary retention",[28,338,339],"Urinary Retention After Procedure","Urinary Retention Postoperative",[341],"urinary retention","2026-01-23",{"date":344,"type":47},"2026-01-30",{"date":346,"type":21},"2026-05-01",{"date":348,"type":21},"2036-05-01",{"name":350,"class":54},"University Hospitals Cleveland Medical Center",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":67,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":86},"100620298","define-final-selection-choice-criteria-for-a-coloplast-catheter-ensuring-highest-patient-satisfaction-via-surveys-eva-100620298","NCT07355803","Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA).","EVA-study on Catheter Selection Criteria at Start of Self-catheterization","EVA","Inclusion Criteria:\n\n* Female or male aged eighteen years or older;\n* Written informed consent;\n* Subject affiliated with a social security scheme or beneficiary;\n* Subject with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder;\n* Subject who received his\u002Fher initial ISC training at the time of inclusion;\n* Subject for whom the expected ISC duration is at least six months;\n* Subject for whom at least two types of Coloplast catheters have been introduced and who has chosen to use Coloplast catheters as the first catheter for self-catheterisation;\n* Subject able to independently conduct ISC;\n* Subject for whom the healthcare professional has recommended to conduct ISC at least four times per day.\n\nExclusion Criteria:\n\n* Vulnerable subject with regard to the current regulation:\n\n  * Pregnant, parturient or breast-feeding woman;\n  * Subject deprived of freedom by judicial, medical or administrative decision;\n  * Underage subject;\n  * Subject is legally protected or unable to express his\u002Fher consent;\n  * Subject not affiliated with or not a beneficiary of a social security scheme;\n  * Subject falling into several categories above;\n* Subject who refused to participate in the study;\n* Subject participating in an interventional clinical study;\n* Subject who, according to the investigator, has cognitive problems that prevent him\u002Fher from completing a questionnaire or for whom the assessment may be a problem.",{"count":360,"type":21},107,[69],"Understanding the Coloplast Intermittent Catheter Selection Study:\n\nThis study aims to understand how adults who need to use catheters to empty their bladder by themselves decide which Coloplast catheter works best for them. The two types of catheters studied are called SpeediCath and Luja.\n\nWhy is this study being done? The study wants to find out which catheter type helps people feel most satisfied when they start to use it on their own. It also looks at why people choose their catheter at the beginning, how happy they are with it over the first six months, and what problems they might face using it.\n\nWho can join the study?\n\n* Adults aged 18 or older who have bladder problems and need to empty their bladder using a catheter.\n* People who have been trained on how to use a catheter.\n* People who have chosen to use either SpeediCath or Luja catheters from Coloplast.\n* People who can perform the catheterization themselves at least two times per day.\n\nCertain people cannot join, such as pregnant women, anyone who cannot give consent, or those who have trouble filling out questionnaires.\n\nWhat will happen in the study?\n\nParticipants will visit the study center three times:\n\n* At the start (to select their catheter and answer questions about the reasons for the specific catheter selection)\n* After 3 to 12 weeks (to share their perception on the impact of the used catheter)\n* After 6 months (to measure final satisfaction and any difficulties)\n\nIf a participant changes to a different catheter type or catheter brand during the study, this will be recorded, and they will continue in the study.\n\nHow will this study help? The information gathered will help healthcare providers understand what matters most to people when selecting a catheter. This can improve how catheters are recommended and support patients better during self-catheterization and improve treatment adherence and compliance.",[364,365,366,28],"Neurogenic Bladder Disorder","Non-Neurogenic Bladder","Bladder Dysfunction","2026-01-13",{"date":369,"type":47},"2026-01-21",{"date":371,"type":47},"2025-10-21",{"date":373,"type":21},"2026-10-28",{"name":375,"class":291},"Coloplast NV\u002FSA",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":63,"minAge":4,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":67,"phases":385,"briefSummary":386,"conditions":387,"keywords":390,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":86},"100619589","effect-of-individualized-catheter-management-on-early-removal-after-rectal-cancer-surgery-100619589","NCT07346586","Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery","Effect of an Individualized Urinary Catheter Management Strategy on the Safety and Efficacy of Early Catheter Removal After Mid-Low Rectal Cancer Surgery: A Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with a preoperative pathological confirmation of rectal malignant tumor.\n2. Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions).\n3. Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME).\n\nExclusion Criteria:\n\n1. History of previous abdominal surgery involving the rectum\u002Fsigmoid colon\u002Fleft colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females).\n2. History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease.\n3. Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy).\n4. Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy.\n5. Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females).\n6. Preoperative assessment indicating potential need for lateral pelvic lymph node dissection.\n7. Preoperative renal insufficiency (serum creatinine level \\>133 μmol\u002FL).\n8. Patients undergoing emergency surgery.\n9. Male patients with preoperative benign prostatic hyperplasia requiring medication.\n10. Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.",{"count":384,"type":21},1545,[69],"This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and an individualized strategy guided by a predictive model (i.e., preventive administration of tamsulosin to high-risk AUR patients prior to catheter removal). The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for individualized postoperative catheter management.",[388,389,28],"Urinary Catheters","Rectal Cancer",[28,389,391],"Catheter","2026-01-08",{"date":394,"type":47},"2026-01-16",{"date":396,"type":21},"2026-02-20",{"date":398,"type":21},"2029-12-20",{"name":400,"class":54},"The First Hospital of Jilin University",{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":224,"minAge":64,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":67,"phases":411,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":86},"100550124","phase-4-evaluation-of-the-efficacy-of-the-addition-of-magnesium-sulfate-to-morphine-on-the-occurrence-of-acute-urinary-retention-following-epidural-anesthesia-for-cesarean-section-100550124","NCT06442995","Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section.","Superiority Randomized Double-blind Controlled Trial of Epidural Magnesium Sulfate Addition Versus Placebo on the Occurrence of Acute Post-caesarean Urinary Retention","EPIMAG","Inclusion Criteria:\n\n* Patients who have undergone scheduled or emergency Caesarean section surgery under extended epidural anesthesia or combined epidural and spinal anesthesia at the Reims University Hospital.\n* Patients who have just undergone caesarean section and have the epidural catheter in place in the post-interventional monitoring room (SSPI).\n* Patients who agree to take part in the research and have signed the informed consent form\n* Patients of legal age\n* Patients affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Minor patients\n* Patients protected by law\n* Patients allergic to local anesthetics, morphine or magnesium sulfate\n* Patients with severe renal insufficiency (GFR \\\u003C 30 ml\u002Fmin)\n* Patients with pre-pregnancy mictional disorders\n* Patients with an American Society of Anesthesiologists (ASA) score of 4\n* Patients undergoing caesarean section under general anaesthesia, after failure of perimedullary anaesthesia\n* Patients with accidental intraoperative injury to the urinary tract\n* Patients who have received intravenous magnesium sulfate in the 24 hours preceding cesarean section",{"count":410,"type":21},290,[412],"PHASE4","Peri-medullary anesthesia is the preferred anesthetic technique for Caesarean surgery. Compared with general anesthesia, it reduces maternal and fetal morbidity and mortality, as well as postoperative pain. However, this technique exposes the patient to the adverse effects of peri-medullary morphine, particularly the risk of postoperative urinary retention. Urinary retention during the first 72 hours after Caesarean section affects around 33% of parturients.\n\nThis is a particularly debilitating event for parturients, exposing them to the risk of further urinary catheterization, increased theoretical risk of urinary tract infection, traumatic urethral injury, hindered accelerated rehabilitation and altered maternal satisfaction.\n\nSeveral studies have demonstrated the benefits of adding magnesium sulfate to epidural anesthesia for Caesarean sections, notably by reducing postoperative pain.\n\nMagnesium sulfate may also have a facilitating effect on postoperative micturition, thanks to its sympathicolytic effect.\n\nThis hypothesis is supported by a retrospective study carried out in our maternity hospital, which showed a 15% reduction in post-Caesarean urinary retention when women were given magnesium sulfate in addition to the drugs traditionally used for epidurals.\n\nThis little-known property needs to be clarified",[28],"2025-12-22",{"date":417,"type":47},"2025-12-30",{"date":419,"type":47},"2025-01-16",{"date":421,"type":21},"2027-12",{"name":423,"class":54},"CHU de Reims",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":224,"minAge":64,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":67,"phases":433,"briefSummary":434,"conditions":435,"keywords":447,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":86},"100607351","incidence-of-pruritus-using-intrathecal-fentanyl-versus-epidural-fentanyl-to-initiate-labour-analgesia-100607351","NCT07187427","Incidence of Pruritus Using Intrathecal Fentanyl Versus Epidural Fentanyl to Initiate Labour Analgesia.","Randomized Trial Comparing the Injection of Intrathecal Fentanyl Versus Epidural Fentanyl for the Initiation of Labour Analgesia on the Incidence of Pruritis.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Vaginal delivery\n* Gestational age ≥ 37 weeks\n* Requesting neuraxial analgesia\n* French or English language\n\nExclusion Criteria:\n\n* ASA score \\> 3\n* Allergy or contraindication to receiving opioids\u002Flocal anesthesia (morphine or fentanyl)\n* BMI \\> 40 kg\u002Fm²\n* Hepatic or renal failure,\n* Severe preeclampsia and signs of severity according to the criteria of the American College of Obstetricians and Gynecologists\n* Maternal hemorrhage (placental abruption, hepatic subcapsular hematoma,...)\n* Severe scoliosis\n* Biliary cholestasis or polymorphic eruption of pregnancy\n* Inability to provide informed consent, either secondary to mental or physical disability or a significant language barrier (inability to understand English or French)\n* Prior administration of an opioid or opioid misuse",{"count":432,"type":21},80,[69],"The purpose of this study is to investigate the effect of neuraxial analgesia initiation on the incidence of pruritus in laboring women. Specifically, this study aim to compare intrathecal fentanyl with epidural fentanyl in order to determine whether the epidural route is associated with a lower occurrence and severity of pruritus. By clarifying these differences, the research seek to optimize analgesic strategies during labor while minimizing opioid-related side effects",[436,437,28,438,439,440,441,442,443,444,445,446],"Pruritis","Hypotension Drug-Induced","Fetal Bradycardia During Labor","Nausea and Vomitting","Satisfaction, Patient","Labor Analgesia","Neuraxial Opioid","Opioid Analgesic Adverse Reaction","Term Labour","Fentanyl Analgesia","Fentanyl Adverse Reaction",[448,449],"neuraxial opioid induced pruritus during labor","Intrathecal fentanyl versus Epidural fentanyl","2025-11-20",{"date":452,"type":47},"2025-11-26",{"date":454,"type":21},"2026-01",{"date":456,"type":21},"2027-05",{"name":458,"class":54},"St. Justine's Hospital",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":67,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":86},"100529890","preoperative-pelvic-floor-physical-therapy-to-minimize-stress-urinary-incontinence-after-holmium-laser-enucleation-of-the-prostate-100529890","NCT06179654","Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate","Inclusion Criteria:\n\n1. Age: \\>=18 years of age\n2. Sex: male sex assigned at birth (needs to have a prostate)\n3. BMI: all BMI\n4. Ethnic background: all ethnicities\n5. Medical history: patients scheduled to undergo HoLEP for BPH\u002FLUTS and associated complications (i.e. gross hematuria, retention, etc.).\n\nExclusion Criteria:\n\n1. Neurological disorders: patients with a history of a neurologic disorder that could affect muscle function, neurogenic bladder, lumbosacral spine pathology\n2. Specific urologic conditions: patients with pre-operative indwelling catheter, urethral stricture greater than 1 centimeter in length or requiring dilation\u002Fincision, indwelling ureteral stent\n3. History of pelvic radiation: patient with prior pelvic radiation will be excluded\n4. Patients unable to give consent\n5. Non-English speaking patients given the need for multiple surveys and telephone follow-ups.",{"count":466,"type":21},36,[69],"The purpose of this study is to allow us to assess the effectiveness (or success) of starting pelvic floor physical therapy (i.e. exercises for your pelvic muscles) prior to HoLEP (holmium laser enucleation of the prostate) surgery for enlarged prostates in order to manage or prevent urinary incontinence (i.e. leaking) after surgery (i.e. post-operatively). Your pelvic floor refers to the muscles under your bladder along your pelvic bones that prevent you from leaking urine or stool. Traditionally, pelvic floor physical therapy is started after surgery and continued until urinary continence (i.e. no leaking of urine) is regained. We want to assess if beginning pelvic floor physical therapy prior to surgery (and continuing afterwards) reduces the time required to regain urinary continence following HoLEP.",[470,28,136],"Benign Prostatic Hyperplasia With Outflow Obstruction","2025-08-20",{"date":473,"type":47},"2025-08-21",{"date":475,"type":47},"2023-11-29",{"date":477,"type":21},"2026-10-31",{"name":479,"class":54},"The Cleveland Clinic",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":67,"phases":490,"briefSummary":491,"conditions":492,"keywords":495,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100599429","relax--feel-at-ease-release-100599429","NCT07084376","RElax & feeL at EASE (RELEASE)","A Multicenter, Parallel-group, Randomized Controlled Trial to Assess the Efficacy of Two Different Educational Approaches on Intermittent Catheter-related Acceptance and Patient-Reported Outcome Measures (PROMs): RElax & feeL at EASE (RELEASE)","RELEASE","Inclusion Criteria:\n\n* Male patients aged 18 years or older.\n* Diagnosed with neurogenic bladder requiring self-managed intermittent catheterization (IC).\n* Currently performing IC or newly prescribed IC.\n* Able to provide informed consent and understand study instructions.\n* Able to understand and complete study questionnaires in Italian.\n\nExclusion Criteria:\n\n* Presence of cognitive impairment limiting ability to understand or perform IC independently.\n* Severe upper limb motor deficits preventing independent catheterization.\n* Active urinary tract infection at baseline.\n* Participation in another interventional study that could interfere with outcomes.\n* Any condition that, in the opinion of the investigators, makes the patient unsuitable for study participation.",{"count":489,"type":21},64,[69],"This multicenter, parallel-group, randomized controlled trial (RELEASE) aims to evaluate the efficacy of two educational approaches on acceptance and adherence to intermittent catheterization (IC) among adult male patients. Participants requiring IC training will be randomized to either an enhanced educational intervention (informational booklet, video tutorial, and standard training) or standard clinical practice training alone. The primary outcome is the change in Intermittent Catheterization Acceptance Test (I-CAT) scores over three months. Secondary outcomes include adherence (I-CAS), urinary symptoms (USQNB-IC), patient autonomy, satisfaction with assistive technology (QUEST), and functional abilities. The study seeks to identify the most effective educational strategy to improve psychological acceptance, promote adherence, and reduce complications in patients performing IC, ultimately supporting patient-centered care and health system efficiency.",[493,494,28],"Incontinence","Neurogenic Bladder Dysfunction",[496,497,498,499,500,501],"Intermittent catheterization","Self-catheterization","Patient education","Adherence","Acceptance","Male urology","2025-07-17",{"date":504,"type":47},"2025-07-24",{"date":506,"type":21},"2025-09-01",{"date":508,"type":21},"2026-09-30",{"name":510,"class":54},"Stefania Musco",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":67,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":86},"100591267","effect-of-urethral-balloon-dilatation-on-urinary-retention-after-spinal-cord-injury-100591267","NCT06978205","Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury","Inclusion Criteria:\n\n1. Age between 18-80 years old\n2. There is a confirmed diagnosis report of CT or MRI imaging, with the first diagnosis being spinal cord injury (complete or incomplete), which conforms to the International Classification of Spinal Cord Injury Neurology published by the American Spinal Injury Association (ASIA) in 2013\n3. The spinal shock period has passed, and consciousness is clear with stable vital signs\n4. In line with the diagnostic criteria of urinary retention and in combination with clinical practice: the patient can urinate autonomously before spinal cord injury, which is confirmed as spinal cord injury by clinical examination. It is manifested as retention of urine after spinal cord injury, swelling of lower abdomen, filling of bladder, dullness on percussion, residual urine volume of bladder B ultrasonic examination is more than 300ml, which shows that urination is laborious\n5. Urodynamic examination shows maximum urethral pressure greater than 50cmH2O\n6. No tumors or benign prostatic hyperplasia were found\n7. Patients who have had their indwelling urinary catheter removed\n8. Voluntary participation in research and signing of informed consent form\n\nExclusion Criteria:\n\n1. Patients with severe heart, brain, lung and other important organ diseases or mental and cognitive disorders\n2. Individuals with disrupted water electrolyte and acid-base balance\n3. There are serious kidney diseases, bladder fistula surgery, anterior urethral sphincterotomy and other diseases\n4. There is a urinary system infection","80 Years",{"count":519,"type":21},74,[69],"Trial Objectives: This clinical trial aims to explore whether ultrasound - guided urethral balloon dilation can effectively improve the micturition function of patients with urinary retention after spinal cord injury, and to evaluate the safety of this treatment method. The main questions it attempts to answer are:\n\nCan ultrasound - guided urethral balloon dilation reduce the residual urine volume and improve the quality of life of patients with urinary retention after spinal cord injury? Trial Design: Researchers will compare the group receiving ultrasound - guided urethral balloon dilation combined with conventional rehabilitation therapy (the experimental group) with the group receiving only conventional rehabilitation therapy (the control group) to determine the therapeutic effect of ultrasound - guided urethral balloon dilation on urinary retention after spinal cord injury.\n\nTasks for Participants:\n\nParticipants in the experimental group will receive ultrasound - guided urethral balloon dilation and cooperate with conventional rehabilitation therapy (including acupuncture therapy, pelvic floor biofeedback electrical stimulation, and pelvic floor function training). Participants in the control group will receive only conventional rehabilitation therapy for a period of 1 - 2 weeks.\n\nDuring the intervention, patients are required to strictly record a micturition diary under the guidance of researchers or medical staff. The diary should cover details such as daily spontaneous urine output, daily catheterized urine output, daily urine leakage volume, and daily frequency of catheterization.\n\nResidual urine volume will be detected every day for three days before the intervention and three days after the intervention.",[523,524,28],"Spinal Cord Injuries (SCI)","Urinary Bladder, Neurogenic",[526,527,341,528,529,530],"Spinal Cord Injuries","neurogenic bladder","Urethral balloon dilation","zelen design","Randomized controlled clinical trial","2025-05-10",{"date":533,"type":47},"2025-05-18",{"date":535,"type":47},"2025-04-28",{"date":346,"type":21},{"name":538,"class":54},"Qilu Hospital of Shandong University",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":224,"minAge":64,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":67,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":86},"100473054","efficacy-of-alpha-blockers-tamsulosin-in-the-treatment-of-symptomatic-dysuria-in-multiple-sclerosis-in-women-100473054","NCT05439902","Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women","ALPHA-SEP","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* Patient with multiple sclerosis (EDSS score \\\u003C 7.5).\n* Moderate to severe dysuria (IPSS score \\> 7) due to bladder sphincter dyssynergia confirmed by complete urodynamic workup.\n* Patient under stable treatment.\n\nExclusion Criteria:\n\n* The subject is participating in another category 1 interventional study, or a trial involving a non-CE marked or CE marked off-label medical device or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Hypersensitivity to tamsulosin hydrochloride, including angioedema induced by the drug or any of the excipients.\n* History of orthostatic hypotension.\n* Severe hepatic impairment.\n* Concomitant treatment with diclofenac, warfarin, CYP3A4 inhibitors.\n* \\- Patient with complete urinary retention at the time of the pre-inclusion consultation, requiring management by intermittent self-catheterization or, failing that, an indwelling bladder catheter from the outset.\n* Major medical or psychiatric illness that, in the opinion of the investigator, would place the subject at risk or could compromise compliance with the study protocol.\n* Presence of another neurological pathology (excluding MS).\n* Swallowing problems that compromise oral medication.\n* Scheduled cataract surgery within 4 months.\n* Pregnant, parturient or breastfeeding patient.",{"count":547,"type":21},60,[69],"Multiple sclerosis (MS) is the leading non-traumatic cause of severe acquired disability in young people. The disease is defined by relapses, which can affect all neurological functions depending on the location of the new inflammatory lesion(s). The disease can thus manifest itself through bladder and bowel disorders (BWS), which affect approximately 80% of MS patients in all stages. Lower urinary tract dysfunction has a significant negative impact on the quality of life of patients and places a significant burden on the healthcare system in terms of resource allocation. In addition, there is a risk of long-term chronic renal failure, an infectious risk (recurrent cystitis and\u002For pyelonephritis, sometimes life-threatening) and a lithiasis risk.\n\nThe most frequently observed urinary symptoms are: urinary frequency, urgency with or without urinary incontinence, dysuria and chronic retention of urine. These disorders most often combine bladder hyperactivity and dysuria. This dysuria may be responsible for recurrent urinary tract infections, lithiasis, alteration of renal function.\n\nThe only therapeutic class currently used to treat dysuria in MS is alpha-blockers. Tamsulosin, alfusozin and doxazosin induce relaxation of the urethral smooth sphincter and prostatic urethral muscle fibers, facilitating the removal of subvesical obstruction and bladder emptying.\n\nThe study investigators hypothesize that treatment with tamsulosin 0.4 mg daily in adult MS patients with dysuria will result in symptom improvement as assessed by the International Prostate Symptom Score (IPSS) and Urinary Symptom Profile (USP) scores, a decrease in post-void residual, and an improvement in urine flow and quality of life.",[551,552,136,553,28],"Multiple Sclerosis","Dysuria","Voiding Dysfunction","2024-06-24",{"date":556,"type":47},"2024-06-25",{"date":558,"type":47},"2022-10-05",{"date":560,"type":21},"2026-03",{"name":562,"class":54},"Centre Hospitalier Universitaire de Nīmes"]